Experimental study examines how sialylation affects basophil activation by galectin-3 in cancer contexts.
Basophils secrete histamine and IL-4/13 when co-cultured with human lung adenocarcinoma cells (A549 cells). Previous studies have revealed that this interaction is dependent on Galectin-3 expression on the surface of A549 cells (EC-Gal-3), IgE present on the surface of IL-3 primed basophils, and direct physical interaction between the two cell types, indicating a cognate interaction between IgE and Gal-3. Reciprocal secretion of pro-tumorigenic cytokines (IL-6/VEGF-A) from A549 cells also results. Here, we further define the biological parameters required for this mode of activation. EC-Gal-3 stimulus has ∼ 20-fold less IgE cross-linking capacity compared with standard anti-IgE. The capacity of IgE-bearing basophils to elicit an EC-Gal-3-mediated response correlates with their responsiveness to standard anti-IgE stimulation, which is known to vary widely among individuals. However, unlike standard anti-IgE stimulation, basophil releasability in response to EC-Gal-3 is influenced by glycosylation patterns on surface-bound IgE. Specifically, bulk sialylation on IgE molecules suppress cellular releasability. Whole cell basophil sialylation also suppresses EC-Gal-3 mediated activation. Gal-3 is an endogenous lectin with multivalent binding capacity and is implicated in a range of diseases involving immune modulation, organ fibrosis, and tumor metastasis. These results can help identify specific physiological and pathophysiological conditions by which IgE:Gal-3 interactions help drive disease processes including wound healing, cancer, and fibrosis, including that which occurs in asthma.
No takes yet. Share an insight, caveat, or question.
Ehrlich et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: